A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

F. Joel Leong, Jay Prakash Jain, Yiyan Feng, Budhaditya Goswami, Daniel S. Stein

ABSTRACT

BACKGROUND: KAF156 is a novel imidazolopiperazine anti-malarial with activity against pre-erythrocytic liver stages, asexual and sexual blood stages. Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 use in combination with piperaquine (PPQ) as both drugs are CYP3A4 substrates and inhibitors. Potential combination effects on the QT interval were also assessed. METHODS: This was an open-label, parallel-group, single-dose study in healthy volunteers randomized to three parallel arms (1:1:1) of 800 mg KAF156 + 1280 mg PPQ, 800 mg KAF156 alone and 1280 mg PPQ alone. Triplicate ECGs were done up to 48 h post-dose. Routine safety and pharmacokinetic assessments were carried out up to 61 days. RESULTS: Of the 72 healthy male subjects recruited, 68 completed the study. Co-administration of PPQ and KAF156 had no overall effect on AUC of either compound, but the Cmax values of both KAF156 (~ 23%) and piperaquine (~ 70%) increased. Both drugs given alone or in combination were well tolerated with no deaths or serious adverse events (SAEs). AEs were observed at the frequency of 87.5, 79.2 and 58.3% respectively for KAF156 + PPQ, PPQ and KAF156 arms. The most common AEs were nausea and headache. There were no Grade 3 or 4 events. There were no ECG related AEs, no QTcF interval > 480 ms and no QTcF interval increase from baseline > 60 ms. There was a positive ∆QTcF trend in the KAF156 + PPQ arm when either KAF156 or piperaquine concentration increases, but there was no significant difference between the combination arm and other arms in maximum ∆QTcF. CONCLUSIONS: No safety/cardiac risk or drug interaction was identified which would preclude use of a KAF156 and PPQ combination in future studies. More... »

PAGES

7

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12936-017-2162-8

DOI

http://dx.doi.org/10.1186/s12936-017-2162-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100201246

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29304859


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Drug Development and Discovery", 
          "id": "https://www.grid.ac/institutes/grid.488724.5", 
          "name": [
            "Novartis Institute for Tropical Diseases, Singapore, Singapore", 
            "D3, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leong", 
        "givenName": "F. Joel", 
        "id": "sg:person.0673166617.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673166617.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt Ltd, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jain", 
        "givenName": "Jay Prakash", 
        "id": "sg:person.01065033023.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065033023.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Institutes for BioMedical Research, Shanghai, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feng", 
        "givenName": "Yiyan", 
        "id": "sg:person.016117401061.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016117401061.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt Ltd, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goswami", 
        "givenName": "Budhaditya", 
        "id": "sg:person.07703173423.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07703173423.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Pharma, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "Daniel S.", 
        "id": "sg:person.01026227546.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026227546.91"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1602250", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001101908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1314981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001751558"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm300041e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004065181"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.04181-14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006760466"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0808859", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011738279"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11203910-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020212832", 
          "https://doi.org/10.2165/11203910-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(15)70032-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024317843"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00340-15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028437055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-015-0312-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030605600", 
          "https://doi.org/10.1007/s40261-015-0312-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.03478-14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039941878"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmp1403340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040800483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12936-015-0664-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041168236", 
          "https://doi.org/10.1186/s12936-015-0664-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12936-015-0664-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041168236", 
          "https://doi.org/10.1186/s12936-015-0664-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)60656-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044151260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.02727-13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046048648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(15)70046-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051340593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.trstmh.2007.05.018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054751495"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm2003359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055952274"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm2003359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055952274"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/138161213804070302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069168496"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: KAF156 is a novel imidazolopiperazine anti-malarial with activity against pre-erythrocytic liver stages, asexual and sexual blood stages. Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 use in combination with piperaquine (PPQ) as both drugs are CYP3A4 substrates and inhibitors. Potential combination effects on the QT interval were also assessed.\nMETHODS: This was an open-label, parallel-group, single-dose study in healthy volunteers randomized to three parallel arms (1:1:1) of 800\u00a0mg KAF156\u00a0+\u00a01280\u00a0mg PPQ, 800\u00a0mg KAF156 alone and 1280\u00a0mg PPQ alone. Triplicate ECGs were done up to 48\u00a0h post-dose. Routine safety and pharmacokinetic assessments were carried out up to 61\u00a0days.\nRESULTS: Of the 72 healthy male subjects recruited, 68 completed the study. Co-administration of PPQ and KAF156 had no overall effect on AUC of either compound, but the Cmax values of both KAF156 (~\u00a023%) and piperaquine (~\u00a070%) increased. Both drugs given alone or in combination were well tolerated with no deaths or serious adverse events (SAEs). AEs were observed at the frequency of 87.5, 79.2 and 58.3% respectively for KAF156\u00a0+\u00a0PPQ, PPQ and KAF156 arms. The most common AEs were nausea and headache. There were no Grade 3 or 4 events. There were no ECG related AEs, no QTcF interval >\u00a0480\u00a0ms and no QTcF interval increase from baseline >\u00a060\u00a0ms. There was a positive \u2206QTcF trend in the KAF156\u00a0+\u00a0PPQ arm when either KAF156 or piperaquine concentration increases, but there was no significant difference between the combination arm and other arms in maximum \u2206QTcF.\nCONCLUSIONS: No safety/cardiac risk or drug interaction was identified which would preclude use of a KAF156 and PPQ combination in future studies.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12936-017-2162-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1030597", 
        "issn": [
          "1475-2875"
        ], 
        "name": "Malaria Journal", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine", 
    "pagination": "7", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e6cb64e01c1b84d06fb3a83adefc376aa9e12577bf56893b973b55f77d62b7b2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29304859"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101139802"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12936-017-2162-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100201246"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12936-017-2162-8", 
      "https://app.dimensions.ai/details/publication/pub.1100201246"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000529.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186/s12936-017-2162-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12936-017-2162-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12936-017-2162-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12936-017-2162-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12936-017-2162-8'


 

This table displays all metadata directly associated to this object as RDF triples.

161 TRIPLES      21 PREDICATES      47 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12936-017-2162-8 schema:about anzsrc-for:11
2 anzsrc-for:1115
3 schema:author N891af60dcc2a4bd9803672547a46da7b
4 schema:citation sg:pub.10.1007/s40261-015-0312-8
5 sg:pub.10.1186/s12936-015-0664-9
6 sg:pub.10.2165/11203910-000000000-00000
7 https://doi.org/10.1016/j.trstmh.2007.05.018
8 https://doi.org/10.1016/s0140-6736(14)60656-5
9 https://doi.org/10.1016/s1473-3099(15)70032-0
10 https://doi.org/10.1016/s1473-3099(15)70046-0
11 https://doi.org/10.1021/jm2003359
12 https://doi.org/10.1021/jm300041e
13 https://doi.org/10.1056/nejmoa0808859
14 https://doi.org/10.1056/nejmoa1314981
15 https://doi.org/10.1056/nejmoa1602250
16 https://doi.org/10.1056/nejmp1403340
17 https://doi.org/10.1128/aac.00340-15
18 https://doi.org/10.1128/aac.02727-13
19 https://doi.org/10.1128/aac.03478-14
20 https://doi.org/10.1128/aac.04181-14
21 https://doi.org/10.2174/138161213804070302
22 schema:datePublished 2018-12
23 schema:datePublishedReg 2018-12-01
24 schema:description BACKGROUND: KAF156 is a novel imidazolopiperazine anti-malarial with activity against pre-erythrocytic liver stages, asexual and sexual blood stages. Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 use in combination with piperaquine (PPQ) as both drugs are CYP3A4 substrates and inhibitors. Potential combination effects on the QT interval were also assessed. METHODS: This was an open-label, parallel-group, single-dose study in healthy volunteers randomized to three parallel arms (1:1:1) of 800 mg KAF156 + 1280 mg PPQ, 800 mg KAF156 alone and 1280 mg PPQ alone. Triplicate ECGs were done up to 48 h post-dose. Routine safety and pharmacokinetic assessments were carried out up to 61 days. RESULTS: Of the 72 healthy male subjects recruited, 68 completed the study. Co-administration of PPQ and KAF156 had no overall effect on AUC of either compound, but the Cmax values of both KAF156 (~ 23%) and piperaquine (~ 70%) increased. Both drugs given alone or in combination were well tolerated with no deaths or serious adverse events (SAEs). AEs were observed at the frequency of 87.5, 79.2 and 58.3% respectively for KAF156 + PPQ, PPQ and KAF156 arms. The most common AEs were nausea and headache. There were no Grade 3 or 4 events. There were no ECG related AEs, no QTcF interval > 480 ms and no QTcF interval increase from baseline > 60 ms. There was a positive ∆QTcF trend in the KAF156 + PPQ arm when either KAF156 or piperaquine concentration increases, but there was no significant difference between the combination arm and other arms in maximum ∆QTcF. CONCLUSIONS: No safety/cardiac risk or drug interaction was identified which would preclude use of a KAF156 and PPQ combination in future studies.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N1a63873ed4664048bb56f49a380c370e
29 N28f4d91e0d4e4bd49c0e326e15d64399
30 sg:journal.1030597
31 schema:name A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine
32 schema:pagination 7
33 schema:productId N0490b1a7c1d24aa3948aeb15aa2ffc42
34 N72e188cf34de4174aa3001b84505af50
35 N81c0022e07fb4193ab5ffe6d0bada50f
36 N94483c60b7ae42ef9a6ea181d25dec7b
37 Ne29837a9748b4678b470db9e44117d6c
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100201246
39 https://doi.org/10.1186/s12936-017-2162-8
40 schema:sdDatePublished 2019-04-10T16:46
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N603dd2125ad642e9a4987677c7e09476
43 schema:url http://link.springer.com/10.1186/s12936-017-2162-8
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N0490b1a7c1d24aa3948aeb15aa2ffc42 schema:name readcube_id
48 schema:value e6cb64e01c1b84d06fb3a83adefc376aa9e12577bf56893b973b55f77d62b7b2
49 rdf:type schema:PropertyValue
50 N1a63873ed4664048bb56f49a380c370e schema:issueNumber 1
51 rdf:type schema:PublicationIssue
52 N28f4d91e0d4e4bd49c0e326e15d64399 schema:volumeNumber 17
53 rdf:type schema:PublicationVolume
54 N3864b64fc1784fe6b9d3917bdca0006a rdf:first sg:person.016117401061.53
55 rdf:rest N80238edf0dfd479c84f66d13258a0d68
56 N4bb65c1c306848af98b37f53fe8d983b rdf:first sg:person.01026227546.91
57 rdf:rest rdf:nil
58 N5d3182e5859a469e9e8ae151768dfc4d schema:name Novartis Institutes for BioMedical Research, Shanghai, People’s Republic of China
59 rdf:type schema:Organization
60 N603dd2125ad642e9a4987677c7e09476 schema:name Springer Nature - SN SciGraph project
61 rdf:type schema:Organization
62 N72e188cf34de4174aa3001b84505af50 schema:name doi
63 schema:value 10.1186/s12936-017-2162-8
64 rdf:type schema:PropertyValue
65 N80238edf0dfd479c84f66d13258a0d68 rdf:first sg:person.07703173423.44
66 rdf:rest N4bb65c1c306848af98b37f53fe8d983b
67 N81c0022e07fb4193ab5ffe6d0bada50f schema:name pubmed_id
68 schema:value 29304859
69 rdf:type schema:PropertyValue
70 N891af60dcc2a4bd9803672547a46da7b rdf:first sg:person.0673166617.65
71 rdf:rest Ne88d4bb2ef1944a7b5b86c8e5ac5fc77
72 N94483c60b7ae42ef9a6ea181d25dec7b schema:name dimensions_id
73 schema:value pub.1100201246
74 rdf:type schema:PropertyValue
75 Ne29837a9748b4678b470db9e44117d6c schema:name nlm_unique_id
76 schema:value 101139802
77 rdf:type schema:PropertyValue
78 Ne88d4bb2ef1944a7b5b86c8e5ac5fc77 rdf:first sg:person.01065033023.67
79 rdf:rest N3864b64fc1784fe6b9d3917bdca0006a
80 Nec68e6dcc83444c789aabb642e6f6607 schema:name Novartis Pharma, East Hanover, NJ, USA
81 rdf:type schema:Organization
82 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
83 schema:name Medical and Health Sciences
84 rdf:type schema:DefinedTerm
85 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
86 schema:name Pharmacology and Pharmaceutical Sciences
87 rdf:type schema:DefinedTerm
88 sg:journal.1030597 schema:issn 1475-2875
89 schema:name Malaria Journal
90 rdf:type schema:Periodical
91 sg:person.01026227546.91 schema:affiliation Nec68e6dcc83444c789aabb642e6f6607
92 schema:familyName Stein
93 schema:givenName Daniel S.
94 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026227546.91
95 rdf:type schema:Person
96 sg:person.01065033023.67 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
97 schema:familyName Jain
98 schema:givenName Jay Prakash
99 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065033023.67
100 rdf:type schema:Person
101 sg:person.016117401061.53 schema:affiliation N5d3182e5859a469e9e8ae151768dfc4d
102 schema:familyName Feng
103 schema:givenName Yiyan
104 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016117401061.53
105 rdf:type schema:Person
106 sg:person.0673166617.65 schema:affiliation https://www.grid.ac/institutes/grid.488724.5
107 schema:familyName Leong
108 schema:givenName F. Joel
109 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673166617.65
110 rdf:type schema:Person
111 sg:person.07703173423.44 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
112 schema:familyName Goswami
113 schema:givenName Budhaditya
114 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07703173423.44
115 rdf:type schema:Person
116 sg:pub.10.1007/s40261-015-0312-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030605600
117 https://doi.org/10.1007/s40261-015-0312-8
118 rdf:type schema:CreativeWork
119 sg:pub.10.1186/s12936-015-0664-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041168236
120 https://doi.org/10.1186/s12936-015-0664-9
121 rdf:type schema:CreativeWork
122 sg:pub.10.2165/11203910-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020212832
123 https://doi.org/10.2165/11203910-000000000-00000
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1016/j.trstmh.2007.05.018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054751495
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1016/s0140-6736(14)60656-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044151260
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1016/s1473-3099(15)70032-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024317843
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1016/s1473-3099(15)70046-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051340593
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1021/jm2003359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055952274
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1021/jm300041e schema:sameAs https://app.dimensions.ai/details/publication/pub.1004065181
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1056/nejmoa0808859 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011738279
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1056/nejmoa1314981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001751558
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1056/nejmoa1602250 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001101908
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1056/nejmp1403340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040800483
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1128/aac.00340-15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028437055
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1128/aac.02727-13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046048648
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1128/aac.03478-14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039941878
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1128/aac.04181-14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006760466
152 rdf:type schema:CreativeWork
153 https://doi.org/10.2174/138161213804070302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069168496
154 rdf:type schema:CreativeWork
155 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
156 schema:name Novartis Healthcare Pvt Ltd, Hyderabad, India
157 rdf:type schema:Organization
158 https://www.grid.ac/institutes/grid.488724.5 schema:alternateName Drug Development and Discovery
159 schema:name D3, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
160 Novartis Institute for Tropical Diseases, Singapore, Singapore
161 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...